Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

New study sheds light on Eliquis and Xarelto switching

By Brian Buntz | August 25, 2023

Apixaban pill anticoagulant medication used to treat and prevent blood clots and prevent stroke in atrial fibrillation

[Adobe Stock]

For patients with an elevated stroke risk, switching anticoagulant medications could be a health gamble. Those who change from Eliquis (apixaban) to Xarelto (rivaroxaban) could face almost double the risk of stroke or severe bleeding. Conversely, sticking with Eliquis or transitioning from rivaroxaban to Eliquis appears to be a safer option.

Those are key takeaways from a retrospective real-world data study presented at the European Society of Cardiology Congress 2023.

ATHENS Study: New insights into Eliquis and Xarelto switching

The ATHENS study focused on patients with non-valvular atrial fibrillation (NVAF) and used a hazard ratio (HR) to quantify the likelihood of stroke or systemic embolism. Specifically, the HR for increased risk for either condition was 1.99, and for major bleeding, it was 1.80, both indicating a substantially elevated risk.

Eliquis has been the subject of several studies at the European Society of Cardiology Congress over the years, starting with a 2008 study evaluating its safety in combination with antiplatelet therapy after acute coronary syndrome. Subsequent research at the congress has generally portrayed Eliquis in a favorable light, highlighting its efficacy, for instance, in stroke prevention and highlighting its safety profile compared to the traditional anticoagulant warfarin.

The latest data from the ATHENS study underscores the need for cautious decision-making when weighing a switch between direct anticoagulant medications such as Eliquis and Xarelto.

Such drugs remain popular thanks in part to growing use to treat conditions such as non-valvular atrial fibrillation (NVAF), a common heart rhythm disorder that ups stroke risk. Last year, Eliquis alone contributed to a combined revenue of more than $18 billion for pharma giants BMS and Pfizer, while Xarelto brought in roughly $7.5 billion for Bayer and Janssen.

Despite their growing use, data has been relatively sparse on the outcomes of switching between direct oral anticoagulants (DOACs), leaving both doctors and patients in somewhat uncharted territory.

One notable example of research in this vein is a 2021 systematic review in the Journal of Thrombosis and Thrombolysis on DOAC-to-DOAC switching. That review, which looked at five large studies involving more than 259,000 patients, found that patients on DOACs were less likely to switch to other DOACs compared to alternatives like dabigatran and rivaroxaban. The study, which pooled odds ratios of 0.29 and 0.58 for switching from apixaban to dabigatran and rivaroxaban, respectively, indicated that apixaban may provide a more stable treatment course.

How real-world data complements randomized controlled trials

While randomized controlled trials remain the gold standard for establishing drug safety and efficacy, they frequently have limited generalizability, and as a result don’t always mirror real-world settings. Conversely, real-world observational studies such as ATHENS can provide insights into how these medications perform in more diverse and complex patient populations.

In a press release, Dr. Narinder Bhalla from Bristol Myers Squibb noted, “Data collected in real-world settings can enhance patient care.” He added that ATHENS data “provides pragmatic information to help clinicians manage the care of their patients.


Filed Under: Cardiovascular, clinical trials, Drug Discovery, Hematology
Tagged With: anticoagulants, ATHENS study, Eliquis, NVAF, real-world data, stroke risk, Xarelto
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Sanofi ramps up distribution of Beyfortus ahead of RSV season
BMS
Label update broadens Camzyos reach in obstructive HCM, trims echo burden for stable patients
FDA logo
FDA drug approvals holding steady at 44 YTD in 2024
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE